Margo Sorgman was diagnosed with an MPN, polycythemia vera (PV), just a few months ago at the age of 71. She shares her story of learning about the condition, meeting with Dr. Brady Stein, and how she’s doing today.
Jeff Folloder, a husband, father, son, and cancer survivor, discusses his own personal journey with CLL and his philanthropic efforts in the cancer community.
Why do I have lung cancer if I’ve never smoked? Dianne Stewart, a stage IV cancer patient, asked herself this question following her diagnosis. Hear about her initial stage of shock and denial and her advice for others.
Research into the treatment and management of chronic lymphocytic leukemia (CLL) is evolving at a record pace and now-more than ever-it is vital for patients to stay informed. Attend online on in-person.
March 29, 2015 - Phoenix, AZ
Dr. Mario Boccadoro shares his perspective on the improving prospects for patients with the disease and comments on efforts to personalize treatment for each patient.
January 31, 2013
Susie Novis, co-founder of the International Myeloma Foundation, joins Andrew at the 2012 ASH meeting to share her perspective on news being presented for patients.
January 24, 2013
Patient advocate, Jack Aiello puts significant news for myeloma patients into perspective.
January 23, 2013
Dr. William Bensinger, myeloma expert from the Seattle Cancer Care Alliance, discusses research results that offer hope for patients who experience disease relapse after an allogeneic stem cell transplant.
January 16, 2013
Dr. William Bensinger shares results from a study reported at ASH 2012 using an older drug, amifostine, in a new way; protecting patients from toxicity while patients receive higher and more effective doses of cancer-fighting drugs.
January 8, 2013
Dr. William Bensinger details results from a phase l trial reported ASH 2012 testing a new, triple drug combination to help relapsed/refractory multiple myeloma patients.
December 13, 2012
The American Society of Hematology President, Dr. Janis Abkowitz, shares a call to action and urges support for continued research funding.
Andrew Schorr shares his optimism while attending the 2012 American Society of Hematology meeting in Atlanta, Georgia.
December 27, 2012
Dr. Michael Keating shares his perspectives on some complex research surrounding CLL treatment expansion.
January 29, 2013
Dr. Michael Keating talks about different approaches for combating aggressive subtypes of CLL.
Dr. Claire Dearden, discusses the latest data demonstrating that ibrutinib is highly effective while other oral medications show promise in clinical research.
Dr. Jeff Sharman discusses how treatments such as chemotherapy and FCR will be a thing of the past while targeted therapies continue to advance with the hope of a decrease in toxicty with an increase of efficacy.
January 22, 2013
Dr. Michael Keating provides an update from ASH 2012 on treatment for CLL beyond the FCR regimen.
Dr. William Wierda discusses updates on Chimeric Antigen Receptor research from ASH 2012.
December 30, 2012
Dr. John Pagel details important advances that signal a changing treatment landscape in CLL with new options for patients, with updates from ASH 2012
Drs. John Byrd and Jan Burger share the latest trial data for ibrutinib from ASH 2012
December 8, 2012
Dr. Jan Cerny explains how this very early animal research is advancing the search for a cure to CML.
February 4, 2013
Dr. Giuseppe Saglio looks to powerful medicines used in combination to not only knock CML cells down but to knock them out.
Jan Geissler shares an encouraging report from the 2012 American Society of Hematology annual meeting.
January 28, 2013
Dr. Moshe Talpaz discusses when the "big guns"of treatment should be used and how there are now treatment options that address certain resistant mutations including the T315I.
January 17, 2013
Executive Director of the National CML Society, Greg Stephens, gives his perspective on news for CML patients from the 2012 ASH Meeting.
December 20, 2012
A promising new treatment brings hope for patients with a rare form of leukemia who have run out of treatment options.
December 10, 2012
New updated research results on Jakafi (ruxolitinib) show positive news to prove to be more effective than hydroxyurea for the treatment of myelofibrosis, according to a new study released at ASH 2012.
December 21, 2012
Dr. Ruben Mesa of the Mayo Clinic, shares his optimism for patients living with myeloproliferative disorders, particularly Myelofibrosis.
December 18, 2012
El tratamiento de las MPN tiene buenas perspectivas; el Dr. Ruben Mesa nos da su opinión tras asistir a la convención ASH.
December 31, 2012
Dr. Steven Park updates us on frontline therapy for patients living with Advanced Hodgkin Lymphoma.
December 19, 2012
Internationally recognized myeloma advocate and mentor, Cynthia Chmielewski talks about the importance – and the gift – of reaching out to others with myeloma.
March 22, 2013
Personalized medicine is the future of myeloma treatment. Dr. Shaji Kumar discusses how the variety of therapies and better understanding of genetic components are coming together to achieve better outcomes.
May 15, 2013
Research is showing that proteasome inhibitors are incredibly effective at treating many stages of myeloma. Dr. Shaji Kumar talks about how this therapy is becoming a new backbone treatment for myeloma.
July 12, 2013
We're learning a lot about choosing the right treatment plan for each patient. Drs. Shaji Kumar and Noopur Raje talk about what information helps them decide the right plan for each patient.
July 11, 2013
By Andrew Schorr